Application of prostate resectoscope in the treatment of massive rectal bleeding after transrectal prostate puncture

Table 1 Clinical and histopathology characteristics of the patients

Case No.	Age (yr)	PSA (ng/mL)	Histopathology	TNM	Gleason	Post puncture treatment	Subsequent treatment
1	54	40.24	Adenocarcinoma	T3N1M1b	4 + 3	CT + TUPRI	ADT + AA
2	66	140.21	Adenocarcinoma	T3N1M1b	4 + 5	CT + TUPRI	ADT + AA
3	76	112.67	Adenocarcinoma	T3N1M1b	4 + 3	CT + Transfusion + DSA + TUPRI	ADT + Enzalutamide
4	56	99.46	Adenocarcinoma	T3N1M1b	4 + 4	CT + TUPRI	RARP + ADT + AA
5	71	122.35	Adenocarcinoma	T3N1M1a	4 + 3	CT + TUPRI	TUVP + ADT
6	66	65.61	Adenocarcinoma	T3N1M1a	4 + 4	CT + Transfusion + DSA + TUPRI	LRP + ADT + AA
7	82	652.64	Adenocarcinoma	T3N1M1b	5 + 4	CT + TUPRI	ADT + Enzalutamide
8	76	126.13	Adenocarcinoma	T3N1M1a	5 + 3	CT + TUPRI	ADT + Enzalutamide

CT: Conventional therapy (rehydration and hemostatic drugs); TUPRI: Transurethral prostate resection instrumentation; ADT: Androgen deprivation therapy; AA: Abiraterone acetate; RARP: Robot-assisted radical prostatectomy; TUVP: Transurrethral vaporizationn prostate; PSA: Prostate-specific antigen; LRP: Laparoscopic radical prostatectomy; DSA: Digital subtraction angiography.